A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Rutgers, The State University of New Jersey
University of Southern California
UNC Lineberger Comprehensive Cancer Center
OHSU Knight Cancer Institute
Emory University
Virginia Commonwealth University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)